Past and Present Smoking Raises Risk of Dermatology Surgery Complications

MedicalResearch.com Interview with:

Ian A. Maher, MD Department of Dermatology St Louis University, St Louis, Missouri

Dr. Maher

Ian A. Maher, MD
Department of Dermatology
St Louis University, St Louis, Missouri 

MedicalResearch.com: What is the background for this study? What are the main findings?

Response: One of our wonderful trainees at Saint Louis University was interested in the role of smoking in flap failures.  Dogma has been that smoking was a major risk factor for flap failures.  Looking at our database as well as published data, flap failures are a rare event, so rare as to be difficult to definitively associate with anything.  We decided to look more broadly at complications both acute (infections failures) and chronic (mainly cosmetic scarring associated) in flaps and grafts. Continue reading

Some Physicians Who Advise FDA Later Form Financial Relationships with Pharmaceutical Companies

MedicalResearch.com Interview with:

Stephanie L. Kuschel, B.A Indiana University School of Medicine Indianapolis, IN, 46202

Dr. Kuschel

Stephanie L. Kuschel, MD
Indiana University School of Medicine
Indianapolis, IN, 46202

Robert Dellavalle, MD, PhD, MSPH
Professor of Dermatology and Public Health
University of Colorado School of Medicine
Colorado School of Public Health
Chief, Dermatology Service
US Department of Veterans Affairs
Eastern Colorado Health Care System
Denver, CO 80220 

MedicalResearch.com: What is the background for this study? What are the main findings? 

Response: Physicians can serve as external experts and voting members of FDA advisory committee panels, which help determine if a drug is acceptable for the US market. Considering that financial conflicts of interest (FCOI) have been shown to influence voting member habits, the FDA has regulations in place to minimize these FCOI. However, the FDA can grant waivers for some financially conflicted individuals if they meet certain requirements (like offering key insights that may out-weigh the risk of a possible FCOI). Additionally the FDA does not make stipulations regarding post-advisory role financial relationships. In fact, many former FDA committee advisors later engage in financial relationships with pharmaceutical companies. Some worry these post-hoc financial relationships could pose an ethical dilemma whereby future FDA advisory members are incentivized to alter their voting habits in expectation of future rewards. Others argue the situation may be more complex than expected.

For example, the author of one study, found that while there was evidence for a pro-industry voting bias among committee members with exclusive financial relationships to the sponsoring manufacturer (of the drug under review), this was not the case for members with nonexclusive financial ties to both the sponsor and its competitors 1. Furthermore, the author found that advisors with many corporate ties were (on average) actually more likely than their peers without any financial ties to vote against the sponsor. The author argued that these advisors were more likely to be experienced researchers, and their voting habits may reflect their experience evaluating medical research.

While this author and others have offered valuable insights into financial relationships of advisors during their advisory role, unfortunately little information is available regarding post-advisory role financial relationships and whether these relationship have any influence on the integrity of the voting process. The purpose of our study was to review Open Payment data on industry payments to former physician FDA dermatologic drug committee members.  Continue reading

Vitiligo: Off Label Topical Calcineurin Inhibitors Help Some Patients

MedicalResearch.com Interview with:

Dr-Jung Min Bae

Dr. Jung Min Bae

Jung Min Bae, MD, PhD
Associate Professor, Department of Dermatology
St. Vincent’s Hospital
College of Medicine, The Catholic University of Korea 

MedicalResearch.com: What is the background for this study?

Response: Vitiligo is a common chronic skin disease affecting 1% of the population, and it causes low self-esteem and social stigma. To date, there are no approved drugs for the treatment of vitiligo, even though growing evidence indicates favorable therapeutic responses of topical calcineurin inhibitors (TCIs) including tacrolimus and pimecrolimus.

In this study, we conducted a systematic review and meta-analysis of all relevant prospective studies (n = 46) and identified remarkable therapeutic responses of TCI monotherapy and TCI plus phototherapy for vitiligo. Continue reading

Don’t Get Burned by Homemade Sunscreens

MedicalResearch.com Interview with:

Lara B. McKenzie, PhD, MA Principal Investigator in the Center for Injury Research and PolicyResearch Institute at Nationwide Children's HospitalAssociate Professor in the Department of PediatricsCollege of Medicine and the Division of EpidemiologyCollege of Public Health at The Ohio State University

Dr. McKenzie

Lara B. McKenzie, PhD, MA
Principal Investigator in the Center for Injury Research and Policy
Research Institute at Nationwide Children’s Hospital
Associate Professor in the Department of Pediatrics
College of Medicine and the Division of Epidemiology
College of Public Health at The Ohio State University

MedicalResearch.com: What is the background for this study? What are the main findings?

Response: Social media and other online tools have changed the way people seek and share health information. Recent consumer interest in natural, organic, and ethically-made personal care products has led to an increase of shared recipes for homemade products including sunscreen.

The study found that nearly all (95%) pins, or bookmarks, for homemade sunscreen positively portrayed the effectiveness of homemade sunscreens and most (68%) recommended recipes for homemade sunscreens that offered insufficient UV radiation protection. Sun Protection Factor (SPF) claims were made in a third of pins with a range of SPF 2 to SPF 50. This is concerning because the ingredients recommended in homemade sunscreen pins offer minimal scientifically proven broad-spectrum protection from UV radiation yet are widely shared and promoted as safe alternatives to commercial sunscreens on Pinterest.

Homemade sunscreen products are risky because they are not regulated or tested for efficacy like commercial sunscreens. When you make it yourself, you don’t know if it’s safe or effective. With rising skin cancer rates, the use of effective broadband sunscreen is critical to protect the skin from UV radiation and reduce incidence of skin cancer.  Continue reading

Novel Bactericidal Gel Offers Promise For Antibiotic-Resistant Acne

MedicalResearch.com Interview with:
Venkateswarlu (Venkat) NelabhotlaPresident & Board MemberVyome Therapeutics Inc., Venkateswarlu (Venkat) Nelabhotla
President & Board Member
Vyome Therapeutics Inc., 

MedicalResearch.com: What is the background for this study?

Response: There are only a handful of antibiotics that are approved for use against the bacterial strain P.acnes that causes acne vulgaris. Because of the lack of new antibiotic treatment options, similar antibiotics are overused resulting in 1 out of 3 patients developing resistance against treatment, ultimately causing a decline in response rates. There is a clear unmet medical need for these patients; currently, patients do not have access to topical antibiotic treatments capable of an effective response without generating resistance. This study was designed to test the efficacy of VB-1953 in such moderate to severe acne patients, who were carrying resistant acne-causing bacteria and had failed to respond to currently approved antibiotics.

VB-1953, a bactericidal topical gel formulated antibiotic, differs from these older generation antibiotics in its novel mechanism of action, through which it can kill both sensitive as well as resistant bacteria, while also reducing inflammation . The earlier generation of antibiotics, including treatments like clindamycin, are bacteriostatic in action, i.e. they merely prevent the growth of acne-causing bacteria. VB-1953 is the first bactericidal antibiotic for the treatment of acne that kills acne-causing bacteria. VB-1953 also retards the development of resistance, and reduces inflammation associated with acne via an independent immunomodulatory effect. 

Continue reading

Laser Microscope Can See and Treat Skin Without Cutting Into It

MedicalResearch.com Interview with:
Haishan Zeng, PhDDistinguished ScientistImaging Unit - Integrative Oncology DepartmentBC Cancer Research CentreProfessor of Dermatology, Pathology, and Physics, University of British ColumbiaVancouver, BC, Canada Haishan Zeng, PhD

Distinguished Scientist
Imaging Unit – Integrative Oncology Department
BC Cancer Research Centre
Professor of Dermatology, Pathology, and Physics, University of British Columbia
Vancouver, BC, Canada 

MedicalResearch.com: What is the background for this study? What are the main findings?

Response: We developed a fast multiphoton microscope system that enables clinical imaging of the skin at the level of cellular resolution. With this system, we can see microstructures inside of the skin without cutting into it. We subsequently conceived the idea of directly treating the microstructures that are responsible for disease. We increased the laser power to generate intense localized heat to destroy the targeted structure. In this study, we demonstrated the feasibility of this new treatment by targeting and closing single blood vessels using our new microscope. 

Continue reading

How Much of Your Sunscreen is Absorbed?

MedicalResearch.com Interview with:

David Strauss, MD, PhDDirector, Division of Applied Regulatory ScienceU.S. Food and Drug AdministrationCenter for Drug Evaluation and Research

Dr. Strauss

David Strauss, MD, PhD
Director, Division of Applied Regulatory Science
U.S. Food and Drug Administration
Center for Drug Evaluation and Research

MedicalResearch.com: What is the background for this study? What are the main findings?

Response: It is unknown whether most active ingredients in sunscreens are absorbed. FDA has provided guidance that sunscreen active ingredients with systemic absorption greater than 0.5 ng/mL or with safety concerns should undergo nonclinical toxicology assessment including systemic carcinogenicity and additional developmental and reproductive studies.

This randomized clinical trial demonstrated systemic exposure of 4 commonly used sunscreen active ingredients on application of sunscreen products under maximal use conditions consistent with current sunscreen labeling.

All 4 sunscreen active ingredients tested resulted in exposures exceeding 0.5 ng/mL.  Continue reading

Are Overweight or Obese Adolescents More or Less Prone to Acne?

MedicalResearch.com Interview with:
Igor Snast, MD

Department of Dermatology
Rabin Medical Center–Beilinson Hospita
Israel. 

MedicalResearch.com: What is the background for this study? What are the main findings?

Response: Acne is the most common skin disorder among adolescents. Obesity has been suggested to promote acne, however various studies evaluating the relationship between obesity and acne have yielded contradictory outcomes.

Our population-based study demonstrates that overweight, obese and severely obese youths have decreased odds of having acne (20%, 35% and 50% respectively) compared to normal-weight subjects. Continue reading

Microbiome in Early Adolescent Acne Changes Over Time

MedicalResearch.com Interview with:

Dr. Jusleen Ahluwalia MDSecond-year Dermatology residentUniversity of California, San Diego

Dr. Ahluwalia

Dr. Jusleen Ahluwalia MD
Second-year Dermatology resident
University of California, San Diego

MedicalResearch.com: What is the background for this study? What are the main findings? 

Response: Preadolescence is an interesting stage during which changes in microbial diversity can coincide with the development of acne. This study is the largest assessment of preadolescent acne microbiome in the literature to date.

In this study, we found that early acne in preadolescent females is characterized by an abundance of Streptococcus mitis, while later stages are characterized by a predominance of Cutibacterium acnes (formerly known as Propionibacterium acnes).  

Continue reading

Overweight and Obese Young Adults at Decreased Risk of Acne

MedicalResearch.com Interview with:
Igor Snast, MD
Department of Dermatology
Rabin Medical Center–Beilinson Hospital
Israel

MedicalResearch.com: What is the background for this study? What are the main findings?

Response: Acne is the most common skin disorder among adolescents. Obesity has been suggested to promote acne, however various studies evaluating the relationship between obesity and acne have yielded contradictory outcomes.

Our population-based study demonstrates that overweight, obese and severely obese youths have decreased odds of having acne (20%, 35% and 50% respectively) compared to normal-weight subjects. Continue reading

Contact Allergic Reactions to Implanted Cardiac Devices

MedicalResearch.com Interview with:

Amber Reck Atwater, M.D.Dermatology Residency Program DirectorAssociate Professor of DermatologyDirector, Contact Dermatitis ClinicDuke Dermatology

Dr. Reck Atwater

Amber Reck Atwater, M.D.
Dermatology Residency Program Director
Associate Professor of Dermatology
Director, Contact Dermatitis Clinic
Duke Dermatology 

MedicalResearch.com: What is the background for this study? What are the main findings?

Response: We completed an evaluation of our Duke Dermatology patients who underwent patch testing for possible allergy to their cardiac devices – pacemakers and defibrillators.

From March 1, 2012 to September 15, 2017 we saw 11 patients with suspected allergy to their devices.  Concern for allergy, skin eruption, skin symptoms, and concern for infection were common. 73% of patients had erythema at their implant scars; pruritus and pain were also noted.  Six of our patients had relevant reactions, and the most common allergies were metals, silicone and rubber accelerators.  Continue reading

Psoriasis: No Difference Found in Cardiovascular Risk Between Ustekinumab vs TNF Inhibitor Therapy

MedicalResearch.com Interview with:

Seoyoung C. Kim, MD, ScD, MSCEDirector, Program in Rheumatologic, Immunologic, and Musculoskeletal PharmacoEpidemiology Associate Professor of MedicineDivision of Pharmacoepidemiology & PharmacoeconomicsDivision of Rheumatology, Immunology and Allergy Brigham and Women's Hospital, Harvard Medical School

Dr. Kim

Seoyoung C. Kim, MD, ScD, MSCE
Director, Program in Rheumatologic, Immunologic, and Musculoskeletal PharmacoEpidemiology
Associate Professor of Medicine
Division of Pharmacoepidemiology & Pharmacoeconomics
Division of Rheumatology, Immunology and Allergy
Brigham and Women’s Hospital
Harvard Medical School

MedicalResearch.com: What is the background for this study?

Response: Given a high cardiovascular (CV) risk among patients with psoriasis and psoriatic arthritis, it is important to have more information with regard to potential effect of different treatment agents on CV risk.

As the number of treatment options for psoriasis and psoriatic arthritis has been rising over the few decades, it is even more crucial to have high-quality evidence on comparative safety of different treatment options so physicians and patients can choose an agent based on the benefit-risk profile of each drug they are considering.

Continue reading

Sleep Disturbances Common in Mothers of Children with Atopic Dermatitis

MedicalResearch.com Interview with:

Dr. Katrina Abuabara

Dr. Abuabara

Dr. Katrina Abuabara, MD, MA, MSCE
Department of Dermatology Program for Clinical Research, University of California, San Francisco

MedicalResearch.com: What is the background for this study?

Response: The wellbeing and development of children is strongly influenced by parents’ physical and psychosocial health. Parents of children with chronic illness, in particular, are susceptible to poor sleep, and previous studies have found major sleep impairments among parents of children with ventilator dependency and cystic fibrosis, but few studies have examined sleep patterns among parents of children with more common chronic illnesses like atopic dermatitis (also known as eczema).

Continue reading

Adult Atopic Dermatitis Linked to Anxiety and Depression, Often Undiagnosed

MedicalResearch.com Interview with:

Dr. Jonathan L. Silverberg MD PhD MPH Assistant Professor in Dermatology Medical Social Sciences and Preventive Medicine Northwestern University, Chicago, Illinois

Dr. Jonathan Silverberg

Dr. Jonathan L. Silverberg MD PhD MPH
Assistant Professor in Dermatology
Medical Social Sciences and Preventive Medicine
northwesternu, Chicago, Illinois

MedicalResearch.com: What is the background for this study? What are the main findings? 

Response: Atopic Dermatitis is characterized by chronic and often severe and debilitating itch, skin pain, sleep disturbances, skin lesions and multiple comorbid health conditions. The signs, symptoms and comorbidities of atopic dermatitis can lead to significant psychosocial distress and mental health burden

We performed a cross-sectional, population-based study of 2893 US adults. We found that adults with atopic dermatitis had more severe symptoms scores for anxiety and depression (Hospital Anxiety and Depression anxiety). Adults with atopic dermatitis also had higher prevalences of anxiety and depression. Mean symptom scores and prevalences of anxiety and depression were even higher in adults with moderate and severe atopic dermatitis compared to those with mild atopic dermatitis. All respondents with severe PO-SCORAD, POEM and PO-SCORAD-itch scores had elevated anxiety and depression scores.

Many adults with atopic dermatitis that had elevated anxiety and depression scores reported no diagnosis of anxiety or depression. 

Continue reading

Suncreens: FDA Proposed Regulations Would Update Testing and Labeling Requirements

MedicalResearch.com Interview with:

Anna Benevente

Anna Benevente

Anna Benevente
Director of product, labeling, and ingredient review at Registrar Corp (registrarcorp.com), an FDA consulting firm that helps companies comply with FDA regulations.
She has been assisting companies with U.S. FDA regulations since 2009.
She and her team have researched thousands of products to determine whether they meet FDA requirements for compliance.

In February 2019, the U.S. Food and Drug Administration (FDA) published a proposed rule to put into effect a final monograph for over-the-counter (OTC) sunscreen drug products.  If finalized, the rule will update conditions under which OTC sunscreen products may be marketed in the United States.  Given the effect this rule could have on the pharmaceutical and cosmetic industries, MedicalResearch.com sat down with Anna Benevente, Director of Product, Labeling, and Ingredient Review at FDA consulting firm Registrar Corp, to dig deeper into the article they recently published on the rule.

MedicalResearch.com:  What is the background for this announcement?

Response:  FDA issues monographs for specific types of over-the-counter (OTC) drug products, which establish conditions under which a drug may be marketed without FDA approval of a New Drug Application (NDA) or Abbreviated New Drug Application (ANDA). The conditions that are established by the monograph include the active ingredients that have been deemed generally recognized as safe and effective (GRASE) and statements that must appear on the labeling in the form of a Drug Facts panel. Sunscreens have never had an effective final monograph.  Instead, they have been largely regulated under enforcement discretion since 2001, when FDA issued a stay on a final monograph for OTC sunscreen drug products.

The Sunscreen Innovation Act (SIA) of 2014 calls for FDA to establish a final monograph for OTC sunscreen by November 26, 2019. If finalized, the rule proposed in February would lift the stay on the final monograph and amend certain regulations for OTC sunscreen drug products.

MedicalResearch.com:  What is enforcement discretion?

Response: FDA rulemaking can take a considerable amount of time.  During this process, FDA may issue guidance or an enforcement policy that specifies stipulations under which the Agency permits the marketing of certain products in the absence of codified regulations.  While these documents are not legally-binding, they often outline provisions where FDA states that the Agency does not intend to take regulatory action.  These provisions are often incorporated into an FDA rule, as we are seeing in the case of this new rule for sunscreen.

MedicalResearch.com:  Would you explain what GRASE ingredients are?

Response: When FDA establishes a monograph for an OTC drug product, the Agency reviews scientific data on ingredients used for that product and classifies them into three categories:

Category I: The ingredient is generally recognized as safe and effective for its intended use.

Category II: The ingredient is not generally recognized as safe and effective for its intended use.  This ingredient may be not safe as a whole, may be not be safe for the specific intended use, or may not be effective for the specific intended use relative to its health risk.

Category III: There is insufficient scientific data to determine whether the ingredient is safe and effective for its intended use.

While a monograph is still in the rulemaking stage, FDA permits the marketing of products formulated with active ingredients that are deemed Category I or Category III. At this time, industry may submit data to support a Category I designation for a Category III ingredient. When the final monograph is published, FDA no longer uses the terms “Category I”, “Category II”, and “Category III.”  Those ingredients that were deemed Category I become “monograph conditions,” while Category II and III ingredients become “nonmonograph conditions” and may not be marketed after the compliance date identified in the final rule.

Q: What are the main products that would require a label change?

Response:The statement of identity for all sunscreen products would be required to list the sunscreen active ingredients in alphabetical order followed by “Sunscreen” and the product’s dosage form (e.g. “Titanium Dioxide, Zinc Oxide Sunscreen Lotion”).  Additionally, the rule proposes formatting changes to sunscreen labels that would make SPF, broad spectrum, and water resistance statements more prominent.

The rule would require all products over 15 SPF to satisfy broad spectrum testing requirements and the associated labeling requirements for broad spectrum products.  Products under 15 SPF that do not satisfy broad spectrum requirements would be required to include “*See Skin Cancer/Skin Aging Alert” next to the SPF value as a reference to the warning required under 21 CFR 201.327(d)(2).

Continue reading

Port Wine Stain Birthmarks in Infants Safely Treated Without Need for General Anesthesia

MedicalResearch.com Interview with:

Roy G. Geronemus, M.D.Director, Laser & Skin Surgery Center of New YorkClinical Professor of DermatologyNew York University Medical CenterNew York, NY 10016

Dr. Geronemus

Roy G. Geronemus, M.D.
Director, Laser & Skin Surgery Center of New York
Clinical Professor of Dermatology
New York University Medical Center
New York, NY 10016

MedicalResearch.com: What is the background for this study? What are the main findings? 

Response: We made the observation in clinical practice that port wine stain birthmarks can be safely and effectively treated in early infancy without the need for general anesthesia. This observation is particularly important because of the FDA warnings regarding multiple exposures to general anesthesia under the age of 3 and the potential impact on neurocognitive development as these patients require multiple treatments.
Continue reading

Risankizumab for Moderate to Severe Psoriasis: High Rates of Durable Clearance Through One Year

MedicalResearch.com Interview with:

Anne Robinson, Pharm DExecutive Scientific DirectorAbbVie

Dr. Robinson

Anne Robinson, Pharm D
Executive Scientific Director
AbbVie

MedicalResearch.com: What is the background for the risankizumab data presented at the American Academy of Dermatology 2019 Annual Meeting?

Response: Abstracts presented by AbbVie at the American Academy of Dermatology (AAD) 2019 Annual Meeting highlight additional data from the Phase 3 clinical trial program evaluating the safety and efficacy of risankizumab, an investigational interleukin-23 (IL-23) inhibitor. The registrational program for risankizumab evaluated more than 2,000 adult patients with moderate to severe plaque psoriasis across four pivotal studies. Continue reading

Oracea® Capsules + Soolantra Cream Effective for Inflammatory Rosacea

MedicalResearch.com Interview with:

Dr. James Q. Del Rosso, D.O., FAOCD, DermatologistResearch Director and Principal InvestigatorDel Rosso Dermatology Research Center, Las Vegas, NVGalderma Consultant

Dr. Del Rosso

Dr. James Q. Del Rosso, D.O., FAOCD, Dermatologist
Research Director and Principal Investigator
Del Rosso Dermatology Research Center, Las Vegas, NV
Galderma Consultant

MedicalResearch.com: What is the background for this study? What are the main findings?

  • The ANSWER study, a 12-week, randomized, multicenter, Phase 4, Phase 3b in Canada and Europe clinical trial, is the first study of its kind to compare the efficacy and safety of combination therapy with Oracea® (doxycycline, USP) 40 mg Capsules + Soolantra® (ivermectin) Cream, 1% versus Soolantra® (ivermectin) Cream, 1% monotherapy in 273 adults with severe papulopustular rosacea (IGA 4) at clinical trial sites in the United States, Canada and Europe (Czech Republic, Poland, Hungary and Germany).
  • Results showed the combination therapy with Oracea Capsules + Soolantra Cream was well tolerated and effective with a faster onset of action than Soolantra Cream given as monotherapy. Key highlights of the study include:
  • The mean reduction in percentage of inflammatory lesions from baseline to Week 12 was significant with combination therapy compared to monotherapy (80.29% vs. 73.56%, respectively; p=0.032).
  • 5 times as many patients taking combination therapy achieved 100% clearance of inflammatory lesions by Week 12 compared with monotherapy (17.8% vs. 7.2%, respectively; p=0.006).
  • Over 2 times as many patients taking combination therapy achieved 100% clear (IGA 0) by Week 12 compared with monotherapy (11.9% vs. 5.1%, respectively; p=0.043).
  • Combination therapy was generally well tolerated and no discontinuation of treatments due to side effects.

Continue reading

Lipomas: Deoxycholic Acid (Kybella®) Can Shrink Tumors Before Removal

MedicalResearch.com Interview with:

Hooman Khorasani, M.D. Cosmetic Surgeon & Mohs Skin Cancer Surgeon Icahn School of Medicine at Mt. Sinai

Dr. Khorasani

Hooman Khorasani, M.D.
Cosmetic Surgeon & Mohs Skin Cancer Surgeon
Icahn School of Medicine at Mt. Sinai

MedicalResearch.com: What is the background for this study?

Response: Lipomas are tumors composed of mature fat cells located just beneath the skin surface. They are the most common soft tissue tumor and are estimated to occur in 1% of the population. These benign tumors are more common in overweight individuals, diabetics, patients with elevated serum cholesterol, and those suffering from familial multiple lipomatosis. Most of these tumors are treated for cosmetic reasons; however, large lipomas can also cause significant functional impairment. Traditional treatment includes surgical removal and / or liposuction.

Deoxycholic acid is a member of the bile acid family that assists in the breakdown of fat. We investigated the use of deoxycholic acid injections to reduce the size of large lipomas prior to surgical removal.

Continue reading

African American Patients with Psoriasis at Even Greater Risk of Atherosclerotic Heart Disease

MedicalResearch.com Interview with:

Francis Alenghat, MD, PhD Assistant Professor of Medicine Section of Cardiology University of Chicago

Dr. Alenghat

Francis Alenghat, MD, PhD
Assistant Professor of Medicine
Section of Cardiology
University of Chicago

MedicalResearch.com: What is the background for this study? What are the main findings?

Response: Psoriasis has been associated with higher rates of atherosclerotic cardiovascular disease (ASCVD), potentially due to higher-than-normal levels of systemic inflammation. Whether this association varies by race was unknown. Also, it was unclear whether patients with psoriasis have more frequent ASCVD because of higher rates of traditional cardiovascular risk factors (smoking, diabetes, hypertension, hyperlipidemia) or because of components intrinsic to psoriasis itself.

We found that, amongst a large population of patients with psoriasis, patients of both sexes and most ages had elevated ASCVD rates compared to those without psoriasis. Overall, African American patients with psoriasis had a 15% ASCVD prevalence, whereas it was 10% in white patients with psoriasis. Increased ASCVD associated with psoriasis occurred at earlier ages in African American patients compared to white patients.

Traditional cardiovascular risk factors were common in patients with psoriasis and appeared to play a large role in the driving the higher rates of ASCVD in these patients, but even in patients with psoriasis but without any documented traditional risk factors, ASCVD rates were elevated compared to patients without psoriasis.  Continue reading

Superficial Radiation Therapy For Non-Melanoma Skin Cancers in the Elderly

MedicalResearch.com Interview with:

William I. Roth MD Dermatology and Dermatological Surgery Boynton Beach, FL

Dr. Roth

William I. Roth MD
Dermatology and Dermatological Surgery
Boynton Beach, FL

MedicalResearch.com: What is the background for this study?

  • This retrospective study reviewed medical records of patients with biopsy-proven, primary cutaneous basal and squamous cell carcinoma (BCC and SCC) lesions on the lower extremities. These patients were treated with the Sensus Healthcare’s Superficial Radiation Therapy SRT-100 Unit between 2011 and 2014. The SRT-100 is most amenable for treating non-melanoma skin cancer (NMSC) in patients aged 65 and older although many younger patients are treated as well when a non-scarring method is desired.
  • The types of skin cancers treated included superficial, well differentiated and moderately differentiated squamous cell carcinomas, squamous cell carcinoma in situ and basal cell carcinomas including infiltrative basal cell carcinomas. Higher energy linear accelerator radiation units have been reported to have a high incidence of healing problems. With the SRT-100 the radiation is concentrated primarily in the higher layers of the skin where the skin cancer is located and thus the treatments are well tolerated.

Continue reading

Mutations Linked to Scarring Hair Loss in African American Women Identified

MedicalResearch.com Interview with:

Cicatricial Alopecia Courtesy of Dr. Amy McMichael MD The Department of Dermatology Wake Forest Baptist Medical Center Winston-Salem, North Carolina 

Cicatricial Alopecia
Courtesy of Dr. Amy McMichael MD
The Department of Dermatology
Wake Forest Baptist Medical Center
Winston-SalemNorth Carolina

Eli Sprecher MD PhD
Professor and Chair, Division of Dermatology
Deputy Director General for R&D and Innovation
Tel Aviv Sourasky Medical Center
Frederick Reiss Chair of Dermatology
Sackler Faculty of Medicine
Tel Aviv University, Tel Aviv, Israel and

MedicalResearch.com: What is the background for this study?

Response: Central centrifugal cicatricial alopecia (CCCA) is a form of hair loss (alopecia) which is extremely common and affects one in every 20 women of African origin. It starts usually during the fourth decade of life. Because it can be inherited from mothers to their children, it is thought to have a genetic basis. On the other hand, it is known to mainly affect women who use to groom their hair intensively. Thus it was thought that the disease stems from some form of inherited susceptibility to the damage incurred to the hair follicle by grooming habits.

In the study we published, we searched for the genetic basis of CCCA.

In contrast with the common form of alopecia (androgenetic alopecia or female pattern alopecia), CCCA is associated with scarring of the scalp skin, which means that once hair is lost, it will likely not re-grow.

Continue reading

Lilly Announces Phase 3 Results for Atopic Dermatitis Treatment

MedicalResearch.com Interview with:

Lotus Mallbris, MD PhD Vice President, Head of Global Immunology Drug Development Platform Team Leader at Lilly

Dr. Mallbris

Lotus Mallbris, MD PhD
Dermatologist and Vice President, Head of Global Immunology Drug Development
Platform Team Leader at Lilly

MedicalResearch.com: What is the background for this study? Would you briefly explain what is meant by atopic dermatitis? How common is this condition? 

Response:The BREEZE-AD1 and BREEZE-AD2 clinical trials are multicenter, randomized, double-blind, placebo-controlled, Phase 3 studies to evaluate the efficacy and safety of baricitinib monotherapy in adult patients with moderate to severe atopic dermatitis. These are two of five studies that will be part of the placebo-controlled data program intended to support global registrations.

Atopic dermatitis, a serious form of eczema, is a chronic, relapsing skin disease characterized by intense itching, dry skin and inflammation that can be present on any part of the body. It affects approximately 1-3 percent of adults worldwide.

Continue reading

Antibiotics for Acne Alter Skin Microbiome

MedicalResearch.com Interview with:

Dr-Luis Garza

Dr. Garza

Luis Garza, MD-PhD
Associate Professor
Department of Dermatology
Johns Hopkins School of Medicine
Baltimore, MD 21287

MedicalResearch.com: What is the background for this study? What are the main findings?  Do you think these findings would be similar with other antibiotics (oral or topical) or with isotretinoin for acne?

Response: We prescribe antibiotics frequently for acne. We certainly know it affects our normal and abnormal bacteria on our skin. But we don’t fully understand how well or not people recover from antibiotics. 

Continue reading

Kidney Transplant Patients at Increased Risk of Skin Cancer, Even After Graft Stops Working

MedicalResearch.com Interview with
"Kidney Model 9" by GreenFlames09 is licensed under CC BY 2.0. To view a copy of this license, visit: https://creativecommons.org/licenses/by/2.0Donal JSextonMD, PhD
Department of Nephrology and Kidney Transplantation
Beaumont Hospital
Royal College of Surgeons in Ireland
Dublin, Ireland

MedicalResearch.com: What is the background for this study? What are the main findings? 

Response: Patients who receive a kidney transplant as treatment for end stage kidney disease are at risk of malignancy due to immunosuppression. In contrast to

other solid organ transplant types, when kidney transplants fail it is possible for recipients to return to dialysis. Immunosuppression is usually reduced or completely stopped when  the allograft fails due to the risk of infection on dialysis.

We decided to investigate what the trajectory of risk for non-melanoma skin cancer and invasive cancers overall (composite group) looked like for patients who have received multiple consecutive kidney transplants with intervening periods of graft failure. We compared cancer risk during periods of allograft failure and periods of functioning kidney transplants.   Continue reading

Melanoma Rates Stable in Australia but Rising in US

MedicalResearch.com Interview with:

Melanoma CDC/ Carl Washington, M.D., Emory Univ. School of Medicine; Mona Saraiya, MD, MPH

Example of one type of melanoma

Dr. Catherine M. Olsen
Associate Professor
Cancer Control Group
QIMR Berghofer Medical Research Institute

MedicalResearch.com: What is the background for this study?

Response: Melanoma incidence and mortality rates are increasing globally. Public health campaigns aiming to reduce sun exposure and use of sunbed have been implemented in many parts of the world, but there is significant variability in terms of the history and reach of these campaigns across countries. We examined melanoma incidence rates in eight different countries with different patterns of sun exposure and varying approaches to melanoma control.

Continue reading

Skin Care Products Make Cotton Fabrics More Flammable

MedicalResearch.com Interview with:

Dr Sarah Hall PhD Senior Lecturer in Forensic Science Anglia Ruskin University

Dr. Hall

Dr Sarah Hall PhD
Senior Lecturer in Forensic Science
Anglia Ruskin University

MedicalResearch.com: What is the background for this study?

Response: We initially started the study in collaboration with Essex Fire and Rescue Services, as we were already doing some research on the recovery of evidence from fire scenes. During a visit to their cold fire scene facility, they described a tragic fatality with extensive fire damage, which didn’t link with the main fuel in the room. Therefore they questioned if a skin cream, regularly used by the victim, could have contributed as a fuel or ignited to initiate the fire and asked if we would do some initial research. Now we are also working with West Yorkshire and Cambridgeshire Fire and Rescue Service, the London Fire Brigade, St Andrews Centre for Plastic Surgery and Burns and the National Fire Chiefs Council.

We initially started the study in collaboration with Essex Fire and Rescue Services, as we were already doing some research on the recovery of evidence from fire scenes. During a visit to their cold fire scene facility, they described a tragic fatality with extensive fire damage, which didn’t link with the main fuel in the room. Therefore they questioned if a skin cream, regularly used by the victim, could have contributed as a fuel or ignited to initiate the fire and asked if we would do some initial research. Now we are also working with West Yorkshire and Cambridgeshire Fire and Rescue Service, the London Fire Brigade, St Andrews Centre for Plastic Surgery and Burns and the National Fire Chiefs Council.

Continue reading

Safety of MRIs in Patients with Tattoos

MedicalResearch.com Interview with:

Dr. Martina Callaghan PhD Head of Physics & Senior Lecturer Wellcome Centre for Human Neuroimaging Institute of Neurology University College London London  

Dr. Callaghan

Dr. Martina Callaghan PhD
Head of Physics & Senior Lecturer
Wellcome Centre for Human Neuroimaging
Institute of Neurology
University College London
London

MedicalResearch.com:  What is the background for this study?  What are the main findings?

Response: As mirrors the situation in the general population, we found that an increasing number of volunteers who were seeking to enter cognitive neuroscience studies at our Centre had tattoos. However, the magnetic fields used in magnetic resonance imaging (MRI) pose a potential safety risk for people with tattoos. A number of case reports have described such incidents.  However, as these describe isolated cases retrospectively, there was not enough information to objectively assess the risk of tattoo-related adverse reactions for persons having an MRI scan.  Therefore, in 2011, we decided to embark upon this first prospective study to quantitatively assess this risk.

Continue reading

Prions from Brain Detectable in Skin Earlier Than Brain Damage

MedicalResearch.com Interview with:

Wenquan Zou, MD, PhD Associate Professor Departments of Pathology and Neurology Director of CJD Skin Project Associate Director National Prion Disease Pathology Surveillance Center Institute of Pathology Case Western Reserve University School of Medicine Cleveland, Ohio 44106

Dr. Wen Quan Zou

Wenquan Zou, MD, PhD
Associate Professor
Departments of Pathology and Neurology
Director of CJD Skin Project
Associate Director
National Prion Disease Pathology Surveillance Center
Institute of Pathology
Case Western Reserve University School of Medicine
Cleveland, Ohio 44106

MedicalResearch.com: What is the background for this study?

Would you briefly explain the significance of prion-induced diseases and why they have been difficult to diagnosis?

Response: Our previous study has demonstrated that infectious prions are detectable in the skin samples of patients with sporadic Creutzfeldt-Jakob disease (sCJD), the most common form of human prion disease, at the terminal stage by the highly sensitive real-time quaking-induced conversion (RT-QuIC) assay and animal-based bioassay.

The prion-induced diseases are significant because they are infectious diseases that can be transmitted inter-species and intra-species. For instance, mad cow disease, a prion disease in cattle, has been documented to transmit to humans. Currently, there are no cures for these fatal diseases.

The definite diagnosis of prion diseases is difficult because it mainly depends on the availability of brain tissues obtained either by biopsy or autopsy for detection of prions. Brain biopsy is highly invasive and it is difficult to be accepted by patients and their families. Even for brain autopsy, it is not always feasible because of religious and cultural limitations in some regions or countries.  Continue reading

Could Keloids Suggest Increased Risk of Breast Cancer?

MedicalResearch.com Interview with:

Lamont R. Jones, MD, MBA Vice Chair Department of Otolaryngology HNS Henry Ford Hospital Facial Plastic and Reconstructive Surgery Director Cleft and Craniofacial Clinic Otolaryngology Service Chief Henry Ford West Bloomfield Hospital

Dr. Jones

Lamont R. Jones, MD, MBA
Vice Chair
Department of Otolaryngology HNS
Henry Ford Hospital
Facial Plastic and Reconstructive Surgery
Director Cleft and Craniofacial Clinic
Otolaryngology Service Chief
Henry Ford West Bloomfield Hospital

MedicalResearch.com: What is the background for this study? What are the main findings?

Response: The objective of this study was to explore the potential link between keloid development and clinical outcomes of African American women with breast cancer.

MedicalResearch.com: Would you briefly explain what is meant by a keloid?

Response: A keloid is a benign fibrorproliferative tumor of the skin which is more common in African Americans which results from injury such as surgery, ear piercing, burns or infection.

MedicalResearch.com: What are the main findings?

Response: Keloid status of an individual may be indicative of a risk to be diagnosed with early-onset, late staged breast cancer. In addition, it was a distinguishing factor among African American women, which may point to a pathological/molecular pathway that predicates their unique cancer risk.

MedicalResearch.com: What should readers take away from your report?

Response: The research results are preliminary. However, because keloids disproportionately affect African American patients, it may serve as a model to better understand how their tissue microenvironment. Moreover, insights into keloid formation may help to identify ancestry specific biomarkers that may be used as future therapeutic targets to treat cancers in African Americans.

MedicalResearch.com: What recommendations do you have for future research as a result of this work? 

Response: Larger prospective or case control studies may provide more information and better determine the potential correlation of keloid status and breast cancer outcomes. 

Citation:

https://www.henryford.com/news/2019/01/keloids-linked-to-early-onset-and-late-stage-breast-cancer

Jan 30, 2019 @ 2:18 pm

The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.